GLMD Galmed Pharmaceuticals Ltd.

Nasdaq galmedpharma.com


$ 0.79 $ -0.11 (-12.45 %)    

Thursday, 20-Nov-2025 13:40:39 EST
QQQ $ 591.05 $ -20.62 (-3.37 %)
DIA $ 459.24 $ -7.44 (-1.59 %)
SPY $ 656.64 $ -16.32 (-2.43 %)
TLT $ 89.20 $ 0.21 (0.24 %)
GLD $ 373.47 $ -1.71 (-0.46 %)
$ 0.9422
$ 0.90
$ 0.79 x 100
$ 0.79 x 100
$ 0.75 - $ 0.90
$ 0.94 - $ 3.61
1,334,270
na
1.56M
$ 1.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 galmed-pharmaceuticals-reports-top-line-results-from-am-001-phase-1-bioavailability-study-demonstrating-enhanced-pharmacokinetic-profile-of-aramchol-meglumine-granules

The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher...

 galmed-pharmaceuticals-q2-eps-063-beats-083-estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate o...

 galmed-pharma-announces-discovery-of-proprietary-pd-blood-based-biomarker-signature-for-aramchol-clinically-advanced-stearoyl-coa-desaturase-1-inhibitor

Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic ...

 galmed-pharmaceuticals-q1-eps-062-beats-089-estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate o...

 galmed-pharma-first-set-of-oncology-studies-show-aramchol-enhances-liver--colorectal-cancer-approved-therapeutic-regorafenib-effects-in-liver-and-colon-cancers-in-vitro-and-in-vivo-models

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combinati...

 galmed-pharmaceuticals--enters-sponsored-project-agreement-with-virginia-commonwealth-university-to-evaluate-aramchols-effect-on-overcoming-drug-resistance-in-gastrointestinal-cancers

Galmed Pharmaceuticals (NASDAQ:GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to e...

 galmed-unveils-pharmacodynamic-blood-markers-for-aramchol

Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights int...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION